Blog
Chemotherapy's Burden Rivals the Cancer Itself: 119 Patients Speak Out
A survey of 119 U.S. endometrial cancer patients, presented at ESMO 2026, found 70% felt the burden of chemotherapy was almost as much as the burden of the cancer itself — fatigue 93%, nausea 82%, muscle cramps 76%, and 59% who felt unprepared. Here is what patients reported, in plain language, and how to prepare.
Your Gut Bacteria May Predict Chemo Side Effects: What a Landmark Mayo Clinic Study Found
A Mayo Clinic study of 1,364 cancer patients, published in the journal Cell, found that gut bacteria are linked to five cancer groups, to survival, and even to who develops diarrhea from the chemotherapy drug 5-FU. Here is what the research means for patients and caregivers, in plain language.
FDA Approves Immunotherapy Plus Chemotherapy for Stage III Colon Cancer: What Patients Need to Know
On October 8, 2026, the FDA approved atezolizumab (Tecentriq) plus chemotherapy after surgery for stage III colon cancer with deficient mismatch repair (dMMR). In the ATOMIC trial, the combination cut the risk of the cancer coming back or death by 50%. Here is what the news means for patients and caregivers, in plain language.